CoChat
Sign Up
Cited by 400Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

The DOI matches its Crossref record.

Frequent Dysregulation of the c-maf Proto-Oncogene at 16q23 by Translocation to an Ig Locus in Multiple Myeloma

Chesi, Marta, Bergsagel, P. Leif, Shonukan, Oluwatoyin O., Martelli, Maria Luisa, Brents, Leslie A., Chen, Theresa, Schröck, Evelin, Ried, Thomas, Kuehl, W. Michael·1998·Blood
DOI 10.1182/blood.v91.12.4457.412k48_4457_4463
Open this paper in CoChat — free account

Abstract

Dysregulation of oncogenes by translocation to an IgH (14q32) or IgL (kappa, 2p11 or lambda, 22q11) locus is a frequent event in the pathogenesis of B-cell tumors. Translocations involving an IgH locus and a diverse but nonrandom array of chromosomal loci occur in most multiple myeloma (MM) tumors even though the translocations often are not detected by conventional cytogenetic analysis. In a continuing analysis of translocations in 21 MM lines, we show that the novel, karyotypically silent t(14;16)(q32.3;q23) translocation is present in 5 MM lines, with cloned breakpoints from 4 lines dispersed over an approximately 500-kb region centromeric to the c-maf proto-oncogene at 16q23. Another line has a t(16;22)(q23;q11), with the breakpoint telomeric to c-maf, so that the translocation breakpoints in these 6 lines bracket c-maf. Only these 6 lines overexpress c-maf mRNA. As predicted for dysregulation of c-maf by translocation, there is selective expression of one c-maf allele in 2 informative lines with translocations. This is the first human tumor in which the basic zipper c-maf transcription factor is shown to function as an oncogene.

Overview

Integrity signals

Registry

Crossref · 10.1182/blood.v91.12.4457.412k48_4457_4463

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Multiple myeloma and MGUS/SMM have two key groups of initiating events: immunoglobulin (IGH) translocations and hyperdiploidy (HY).

    “Historically, MM and MGUS/SMM have two key groups of initiating events: immunoglobulin (IGH) translocations and hyperdiploid (HY).9,54-59”

    From Evolution of Multiple Myeloma from a Genomic Perspective (2026) · cites this paper as [55]

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 28

  1. Korsmeyer, 1992, Chromosomal translocations in lymphoid malignancies reveal novel proto-oncogenes., Annu Rev Immunol, 10, 785, 10.1146/annurev.iy.10.040192.004033 · DOI
  2. Nishida, 1997, The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization., Blood, 90, 526, 10.1182/blood.V90.2.526.526_526_534 · DOI
  3. Bergsagel, 1996, Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma., Proc Natl Acad Sci USA, 93, 13931, 10.1073/pnas.93.24.13931 · DOI · Paper page
  4. Chesi, 1996, Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines., Blood, 88, 674, 10.1182/blood.V88.2.674.bloodjournal882674 · DOI
  5. Chesi, 1997, Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3., Nat Genet, 16, 260, 10.1038/ng0797-260 · DOI · Paper page
  6. Iida, 1997, Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma., Nat Genet, 17, 226, 10.1038/ng1097-226 · DOI
  7. Lai, 1995, Improved cytogenetics in multiple myeloma: A study of 151 patients including 117 patients at diagnosis., Blood, 85, 2490, 10.1182/blood.V85.9.2490.bloodjournal8592490 · DOI
  8. Sawyer, 1995, Cytogenetic findings in 200 patients with multiple myeloma., Cancer Genet Cytogenet, 82, 41, 10.1016/0165-4608(94)00284-I · DOI
  9. Taniwaki, 1994, Nonrandom chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia., Blood, 84, 2283, 10.1182/blood.V84.7.2283.bloodjournal8472283 · DOI
  10. Pegoraro, 1989, The human myeloma cell line LP-1: A versatile model in which to study early plasma-cell differentiation and c-myc activation., Blood, 73, 1020, 10.1182/blood.V73.4.1020.1020 · DOI
  11. Yoshida, 1991, Localization of the human MAF protooncogene on chromosome 16 to bands q22-q23., Cytogenet Cell Genet, 58, 2003
  12. Bergsagel, 1995, Genes expressed selectively in murine and human plasma cell neoplasms., Curr Top Microbiol Immunol, 194, 57
  13. Kurschner, 1995, The maf proto-oncogene stimulates transcription from multiple sites in a promoter that directs Purkinje neuron-specific gene expression., Mol Cell Biol, 15, 246, 10.1128/MCB.15.1.246 · DOI
  14. Bellamy, 1991, Development and characterization of a melphalan-resistant human multiple myeloma cell line., Cancer Res, 51, 995
  15. Avet-Loiseau, 1997, High incidence of Ig heavy chain gene rearrangements with various partner chromosomes in multiple myeloma, as shown by molecular cytogenetics., Blood, 90, 89a
  16. Vaandrager, 1997, The t(11;14) (q13;q32) in multiple myeloma cell line KMS12 has its 11q13 breakpoint 330 kb centromeric from the cyclin D1 gene [letter; comment]., Blood, 89, 349, 10.1182/blood.V89.1.349 · DOI
  17. Vaandrager, 1996, Direct visualization of dispersed 11q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization., Blood, 88, 1177, 10.1182/blood.V88.4.1177.bloodjournal8841177 · DOI
  18. Taub, 1984, A novel alteration in the structure of an activated c-myc gene in a variant t(2;8) Burkitt lymphoma., Cell, 37, 511, 10.1016/0092-8674(84)90381-7 · DOI
  19. Adachi, 1989, Variant translocation of the bcl-2 gene to immunoglobulin lambda light chain gene in chronic lymphocytic leukemia., Proc Natl Acad Sci USA, 86, 2771, 10.1073/pnas.86.8.2771 · DOI
  20. Komatsu, 1994, A variant chromosome translocation at 11q13 identifying PRAD1/cyclin D1 as the BCL-1 gene., Blood, 84, 1226, 10.1182/blood.V84.4.1226.bloodjournal8441226 · DOI
  21. Nishizawa, 1989, v-maf, a viral oncogene that encodes a “leucine zipper” motif., Proc Natl Acad Sci USA, 86, 7711, 10.1073/pnas.86.20.7711 · DOI
  22. Kataoka, 1993, Structure-function analysis of the maf oncogene product, a member of the b-Zip protein family., J Virol, 67, 2133, 10.1128/JVI.67.4.2133-2141.1993 · DOI
  23. Klein, 1995, Interleukin-6 in human multiple myeloma., Blood, 85, 863, 10.1182/blood.V85.4.863.bloodjournal854863 · DOI
  24. Nacheva, 1990, A new human plasma cell line, Karpas 620, with translocations involving chromosomes 1, 11 and 14., Br J Haematol, 74, 70, 10.1111/j.1365-2141.1990.tb02540.x · DOI
  25. Rao, 1997, Karyotypic complexity of multiple myeloma defined by multicolor spectral karyotyping., Blood, 90, 87a
  26. Zhang, 1994, Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma., Blood, 83, 3654, 10.1182/blood.V83.12.3654.bloodjournal83123654 · DOI
  27. Han, 1997, V(D)J recombinase activity in a subset of germinal center B lymphocytes [see comments]., Science, 278, 301, 10.1126/science.278.5336.301 · DOI
  28. Dib, 1996, A comprehensive genetic map of the human genome based on 5,264 microsatellites [see comments]., Nature, 380, 152, 10.1038/380152a0 · DOI

Cited by

Sorted by citations

Metadata

Authors
Chesi, M., Bergsagel, P. L., Shonukan, O. O., Martelli, M. L., Brents, L. A., Chen, T., Schröck, E., Ried, T., & Kuehl, W. M.
Affiliations
  • National Institutes of Health (US)
  • From the Genetics Department, Medicine Branch, National Cancer Institute, Bethesda, MD; the Department of Medicine, Division of Hematology and Oncology, Cornell University Medical College, New York, NY; and the Genome Technology Branch, National Institutes of Health-National Center for Human Genome Research, Bethesda, MD.
ORCID
Venue
Blood
Publisher
American Society of Hematology
Published
1998-06-15
Volume
91
Issue
12
Pages
4457-4463
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
DOI
10.1182/blood.v91.12.4457.412k48_4457_4463
OpenAlex
W180015230
Cited by
400
References
0
Citations by year
2026: 1 · 2025: 4 · 2024: 5 · 2023: 9 · 2022: 6 · 2021: 9 · 2020: 2 · 2019: 11 · 2018: 7 · 2017: 8 · 2016: 7 · 2015: 12 · 2014: 11 · 2013: 13 · 2012: 15
FWCI
14.33
Type
journal article
Language
en
Open access
closed
Locations
  • Blood (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords
multiple myeloma, chromosomal translocation, 22)(q23, IGH locus, B-cell malignancies, allele-specific expression, breakpoint mapping
MeSH terms
Proto-Oncogene Mas, Amino Acid Sequence, Chromosomes, Human, Pair 14, Chromosomes, Human, Pair 16, DNA-Binding Proteins, Genes, Immunoglobulin, Humans, Immunoglobulin Heavy Chains, Molecular Sequence Data, Multiple Myeloma, Proto-Oncogene Proteins, Translocation, Genetic, Tumor Cells, Cultured, Gene Expression Regulation, Neoplastic, In Situ Hybridization, Fluorescence, Chromosomes, Artificial, Yeast, Proto-Oncogene Proteins c-maf

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review